Assessing the Outcome of Holmium Laser Enucleation of the Prostate by Age, Prostate Volume, and a History of Blood Thinning Agents: Report from a Single-Center Series of >1800 Consecutive Cases
Philipp Gild, Lukas Lenke, Raisa S. Pompe, Malte W. Vetterlein, Tim A. Ludwig, Armin Soave, Felix K.‐H. Chun, Sascha Ahyai, Roland Dahlem, Margit Fisch, Michael Rink, Christian P. Meyer, Andreas Becker
Abstract
Purpose: To assess perioperative outcomes of holmium laser enucleation of the prostate (HoLEP) in a real-world scenario and with a focus on demanding patient factors, such as large prostate size, advanced patient age, and anticoagulation therapy (AT). Materials and Methods: We retrospectively analyzed HoLEP procedures at our institution between 2010 and 2016. After stratification by prostate volume, age, and AT, perioperative and early voiding characteristics were compared. A multivariable regression model was employed to identify predictors of prolonged time of catheterization (defined as being above group's median). Results: The study cohort consisted of 1816 men with a median age of 71 years (interquartile range [IQR]: 66–76), a median prostate volume of 80 mL (IQR: 58–105), and American Society of Anesthesiologists score ≥3 in 618 men (34%). Median time of enucleation and morcellation was 43 minutes (IQR: 31–60) and 10 minutes (IQR: 6–18), respectively. Perioperative blood transfusions were administered in 44 (2.4%) cases, severe postoperative complications (Clavien–Dindo grade ≥3b) occurred in 61 (3.3%) cases. The median time of catheterization was 2 days (IQR: 2–2), with prolonged catheterization occurring in 277 (15%) cases. After adjustment, large prostates (fourth volume quartile [106–280 mL]) (odds ratio [OR]: 1.8, 95% confidence interval [CI]: 1.3–2.6, p = 0.001), therapeutic low-molecular-weight heparin bridging regimen (OR: 2.2, 95% CI: 1.4–3.6, p = 0.037), low-dose acetylsalicylic acid (OR: 1.5, 95% CI: 1.0–2.2, p = 0.015), and a history of direct oral anticoagulation (OR: 2.3, 95% CI: 1.2–4.0, p = 0.022), but not patient age, were independently associated with prolonged catheterization. Conclusions: We confirm HoLEP as safe and efficient; however, patients with large prostates and patients with a history of AT are at risk of prolonged catheterization.